Advances in aptamers screening and the applications in cancer therapy

doi:10.3760/cma.j.cn371439-20240920-00051

Abstract

Abstract:

Aptamers are a class of short DNA/RNA single strand oligonucleotides that can bind to target molecules with high affinity specificity. They have the advantages of high affinity specificity， low molecular weight and low immunogenicity， and have been widely used in biomedical research， clinical diagnosis and therapy， and biosensor development. Systematic evolution of ligand by exponential enrichment （SELEX） is an in vitro screening technique， which enriches the aptamers with high affinity and specific binding to the target through multiple cycles of screening， and has a wide range of applications in tumor therapy.

Key words: Aptamer, SELEX aptamer technique, Antineoplastic protocols

Zheng Siqi, Guo Ting, Wang Jing, Tian Yinghong, Zhang Xingmei. Advances in aptamers screening and the applications in cancer therapy[J]. Journal of International Oncology, 2025, 52(5): 304-308.

References 39

[1]	Qian S, Chang D, He S, et al. Aptamers from random sequence space: accomplishments, gaps and future considerations[J]. Anal Chim Acta, 2022, 1196: 339511. DOI: 10.1016/j.aca.2022.339511.
[2]	Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands[J]. Nature, 1990, 346(6287): 818-822. DOI: 10.1038/346818a0.
[3]	Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase[J]. Science, 1990, 249(4968): 505-510. DOI: 10.1126/science.2200121. pmid: 2200121
[4]	Wu L, Zhang Y, Wang Z, et al. Aptamer-based cancer cell analysis and treatment[J]. ChemistryOpen, 2022, 11(10): e202200141. DOI: 10.1002/open.202200141.
[5]	Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications[J]. Molecules, 2019, 24(5): 941. DOI: 10.3390/molecules24050941.
[6]	Zhu C, Feng Z, Qin H, et al. Recent progress of SELEX methods for screening nucleic acid aptamers[J]. Talanta, 2024, 266(Pt 1): 124998. DOI: 10.1016/j.talanta.2023.124998.
[7]	Lyu C, Khan IM, Wang Z. Capture-SELEX for aptamer selection: a short review[J]. Talanta, 2021, 229: 122274. DOI: 10.1016/j.talanta.2021.122274.
[8]	Zhu C, Yang G, Ghulam M, et al. Evolution of multi-functional capillary electrophoresis for high-efficiency selection of aptamers[J]. Biotechnol Adv, 2019, 37(8): 107432. DOI: 10.1016/j.biotechadv. 2019.107432.
[9]	Jing M, Bowser MT. Isolation of DNA aptamers using micro free flow electrophoresis[J]. Lab Chip, 2011, 11(21): 3703-3709. DOI: 10.1039/c1lc20461k. pmid: 21947169
[10]	Li Y, Tam WW, Yu Y, et al. The application of aptamer in biomarker discovery[J]. Biomark Res, 2023, 11(1): 70. DOI: 10. 1186/s40364-023-00510-8.
[11]	Sun X, Xie L, Qiu S, et al. Elucidation of CKAP4-remodeled cell mechanics in driving metastasis of bladder cancer through aptamer-based target discovery[J]. Proc Natl Acad Sci U S A, 2022, 119(16): e2110500119. DOI: 10.1073/pnas.2110500119.
[12]	Yu F, Chen J, Wang Z, et al. Screening aptamers for serine β- lactamase-expressing bacteria with precision-SELEX[J]. Talanta, 2021, 224: 121750. DOI: 10.1016/j.talanta.2020.121750.
[13]	Nikam PS, Palachandra S, Kingston JJ. In vitro selection and characterization of ssDNA aptamers by cross-over SELEX and its application for detection of S. Typhimurium[J]. Anal Biochem, 2022, 656: 114884. DOI: 10.1016/j.ab.2022.114884.
[14]	Duan Y, Zhang C, Wang Y, et al. Research progress of whole-cell-SELEX selection and the application of cell-targeting aptamer[J]. Mol Biol Rep, 2022, 49(8): 7979-7993. DOI: 10.1007/s11033-022-07317-0. pmid: 35274201
[15]	Wen K, Chen Y, Meng X, et al. A microfluidic dual-aptamer sandwich assay for rapid and cost-effective detection of recombinant proteins[J]. Microchem J, 2023, 188: 108454. DOI: 10.1016/j.microc.2023.108454.
[16]	Chang D, Wang Z, Flynn CD, et al. A high-dimensional microfluidic approach for selection of aptamers with programmable binding affinities[J]. Nat Chem, 2023, 15(6): 773-780. DOI: 10.1038/s41557-023-01207-z. pmid: 37277648
[17]	Qiao N, Li J, Wu X, et al. Speeding up in vitro discovery of structure-switching aptamers via magnetic cross-linking precipitation[J]. Anal Chem, 2019, 91(21): 13383-13389. DOI: 10.1021/acs.analchem.9b00081. pmid: 31580650
[18]	Liu J, Duan Q, Shao Z, et al. Formaldehyde cross-linking-assisted phase separation for protein aptamer selection[J]. Anal Chem, 2023, 95(16): 6700-6708. DOI: 10.1021/acs.analchem.3c00434. pmid: 37052573
[19]	Komarova N, Barkova D, Kuznetsov A. Implementation of high-throughput sequencing (HTS) in aptamer selection technology[J]. Int J Mol Sci, 2020, 21(22): 8774. DOI: 10.3390/ijms21228774.
[20]	Guo L, Song Y, Yuan Y, et al. Identification of nucleic acid aptamers against lactate dehydrogenase via SELEX and high-throughput sequencing[J]. Anal Bioanal Chem, 2021, 413(17): 4427-4439. DOI: 10.1007/s00216-021-03397-2. pmid: 34028561
[21]	Ferreira D, Barbosa J, Sousa DA, et al. Selection of aptamers against triple negative breast cancer cells using high throughput sequencing[J]. Sci Rep, 2021, 11(1): 8614. DOI: 10.1038/s41598-021-87998-y.
[22]	Yazdian-Robati R, Bayat P, Oroojalian F, et al. Therapeutic applications of AS1411 aptamer, an update review[J]. Int J Biol Macromol, 2020, 155: 1420-1431. DOI: 10.1016/j.ijbiomac.2019.11.118. pmid: 31734366
[23]	Mehrnia SS, Hashemi B, Mowla SJ, et al. Radiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles[J]. Radiat Oncol, 2021, 16(1): 33. DOI: 10.1186/s13014-021-01751-3.
[24]	Huang BT, Lai WY, Yeh CL, et al. AptBCis1, an aptamer-cisplatin conjugate, is effective in lung cancer leptomeningeal carcinomatosis[J]. ACS Nano, 2024, 18(41): 27905-27916. DOI: 10.1021/acsnano.4c04680.
[25]	Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023, 77(5): 1773-1796. DOI: 10.1002/hep.32740.
[26]	Wang Z, Wu C, Liu J, et al. Aptamer-mediated hollow MnO₂ for targeting the delivery of sorafenib[J]. Drug Deliv, 2023, 30(1): 28-39. DOI: 10.1080/10717544.2022.2149897.
[27]	Zhang Y, Bi J, Huang J, et al. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications[J]. Int J Nanomedicine, 2020, 15: 6917-6934. DOI: 10.2147/ijn.S264498.
[28]	张渊, 白芷玉, 李琪, 等. 外泌体在恶性肿瘤中的研究现状[J]. 国际肿瘤学杂志, 2023, 50(8): 484-488. DOI: 10.3760/cma.j.cn371439-20230315-00092.
[29]	Han Q, Xie QR, Li F, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer[J]. Theranostics, 2021, 11(13): 6526-6541. DOI: 10. 7150/thno.53886. pmid: 33995674
[30]	Tran PHL, Wang T, Yin W, et al. Aspirin-loaded nanoexosomes as cancer therapeutics[J]. Int J Pharm, 2019, 572: 118786. DOI: 10.1016/j.ijpharm.2019.118786.
[31]	Yang Y, Sun X, Xu J, et al. Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy[J]. ACS Nano, 2020, 14(8): 9562-9571. DOI: 10.1021/acsnano. 9b09884. pmid: 32584540
[32]	Peng JJ, Wang L, Li Z, et al. Metabolic challenges and interventions in CAR T cell therapy[J]. Sci Immunol, 2023, 8(82): eabq3016. DOI: 10.1126/sciimmunol.abq3016.
[33]	Liu CG, Wang Y, Liu P, et al. Aptamer-T cell targeted therapy for tumor treatment using sugar metabolism and click chemistry[J]. ACS Chem Biol, 2020, 15(6): 1554-1565. DOI: 10.1021/acschembio.0c00164.
[34]	Menon AP, Villanueva H, Meraviglia-Crivelli D, et al. CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer[J]. Mol Ther Nucleic Acids, 2024, 35(2): 102198. DOI: 10.1016/j.omtn.2024.102198.
[35]	Porreca I, Blassberg R, Harbottle J, et al. An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation[J]. Mol Ther, 2024, 32(8): 2692-2710. DOI: 10.1016/j.ymthe.2024.06.033.
[36]	Liu Y, Qian X, Ran C, et al. Aptamer-based targeted protein degradation[J]. ACS Nano, 2023, 17(7): 6150-6164. DOI: 10. 1021/acsnano.2c10379.
[37]	He S, Gao F, Ma J, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer[J]. Angew Chem Int Ed Engl, 2021, 60(43): 23299-23305. DOI: 10.1002/anie.202107347.
[38]	Zhang L, Li L, Wang X, et al. Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin[J]. Mol Ther Nucleic Acids, 2022, 30: 66-79. DOI: 10.1016/j.omtn.2022.09.008.
[39]	Wang Y, Yang G, Zhang X, et al. Antitumor effect of anti-c-Myc aptamer-based PROTAC for degradation of the c-Myc protein[J]. Adv Sci (Weinh), 2024, 11(26): 2309639. DOI: 10.1002/advs. 202309639.